The University of Southampton
University of Southampton Institutional Repository

A Disintegrin and Metalloproteinase Domain-9: A novel proteinase culprit with multifarious contributions to COPD

A Disintegrin and Metalloproteinase Domain-9: A novel proteinase culprit with multifarious contributions to COPD
A Disintegrin and Metalloproteinase Domain-9: A novel proteinase culprit with multifarious contributions to COPD

INTRODUCTION: Proteinases with a disintegrin and a metalloproteinase domain (ADAMs) have not been well studied in COPD. We investigated whether ADAM9 is linked to COPD in humans and mice.

METHODS: ADAM9 blood and lung levels were measured in COPD patients versus controls, and air- versus cigarette smoke (CS)-exposed wild-type (WT) mice. WT and Adam9-/- mice were exposed to air or CS for 1-6 months, and COPD-like lung pathologies were measured.

RESULTS: ADAM9 staining was increased in lung epithelial cells and macrophages in smokers and even more so in COPD patients and correlated directly with pack-year smoking history and inversely with airflow obstruction and/or FEV1 % predicted. Bronchial epithelial cell ADAM9 mRNA levels were higher in COPD patients than controls and correlated directly with pack-year smoking history. Plasma, BALF and sputum ADAM9 levels were similar in COPD patients and controls. CS exposure increased Adam9 levels in WT murine lungs. Adam9-/- mice were protected from emphysema development, small airway fibrosis, and airway mucus metaplasia. CS-exposed Adam9-/- mice had reduced lung macrophage counts, alveolar septal cell apoptosis, lung elastin degradation, and shedding of VEGFR2 and EGFR in BALF samples. Recombinant ADAM9 sheds EGF and VEGF receptors from epithelial cells to reduce activation of the Akt pro-survival pathway and increase cellular apoptosis.

CONCLUSIONS: ADAM9 levels are increased in COPD lungs and linked to key clinical variables. Adam9 promotes emphysema development, and large and small airway disease in mice. Inhibition of ADAM9 could be a therapeutic approach for multiple COPD phenotypes.

Journal Article
1073-449X
1500-1518
Wang, Xiaoyun
b11c0deb-d40b-4012-a4f7-5544d3bbe396
Polverino, Francesca
491c416d-8cdc-4b76-8045-31ac7cd8ec23
Rojas-Quintero, Joselyn
7f6ca09f-6fe1-404a-bd6d-3fa0fb460990
Zhang, Duo
4bb8e665-3e0a-4638-b737-fe11a3e6e5d7
Sánchez, José
efed626e-f782-4d25-9418-a81f7c8fb45b
Yambayev, Ilyas
2154ac93-8f09-48ba-85ad-20c84bbbe424
Lindqvist, Eva
29aeb1d6-8e86-40af-b66a-b2f56a497eea
Virtala, Robert
eb1569c7-cde2-40d5-a42b-2ac59b6c52d2
Djukanovic, Ratko
d9a45ee7-6a80-4d84-a0ed-10962660a98d
Davies, Donna E.
7de8fdc7-3640-4e3a-aa91-d0e03f990c38
Wilson, Susan
21c6875d-6870-441b-ae7a-603562a646b8
O'Donnell, Rory
1caff59c-ac09-49cb-8d03-ca85be62613e
Cunoosamy, Danen
ea10b74c-a759-4a17-b71e-e6f20bdd6274
Hazon, Petra
0a0a1f3e-d339-4e65-8a9b-a0b052c7ac9b
Higham, Andrew
d88319ca-aab2-4b79-a3f5-d1330809cc79
Singh, Dave
5a8e5ba8-f961-4422-9a21-a6ef346041e5
Olsson, Henric
bdd651ee-bc1e-40ec-9d1e-17efe7419c7a
Owen, Caroline A.
e8d7464d-82d7-4457-b9d6-315f772c5ccc
Wang, Xiaoyun
b11c0deb-d40b-4012-a4f7-5544d3bbe396
Polverino, Francesca
491c416d-8cdc-4b76-8045-31ac7cd8ec23
Rojas-Quintero, Joselyn
7f6ca09f-6fe1-404a-bd6d-3fa0fb460990
Zhang, Duo
4bb8e665-3e0a-4638-b737-fe11a3e6e5d7
Sánchez, José
efed626e-f782-4d25-9418-a81f7c8fb45b
Yambayev, Ilyas
2154ac93-8f09-48ba-85ad-20c84bbbe424
Lindqvist, Eva
29aeb1d6-8e86-40af-b66a-b2f56a497eea
Virtala, Robert
eb1569c7-cde2-40d5-a42b-2ac59b6c52d2
Djukanovic, Ratko
d9a45ee7-6a80-4d84-a0ed-10962660a98d
Davies, Donna E.
7de8fdc7-3640-4e3a-aa91-d0e03f990c38
Wilson, Susan
21c6875d-6870-441b-ae7a-603562a646b8
O'Donnell, Rory
1caff59c-ac09-49cb-8d03-ca85be62613e
Cunoosamy, Danen
ea10b74c-a759-4a17-b71e-e6f20bdd6274
Hazon, Petra
0a0a1f3e-d339-4e65-8a9b-a0b052c7ac9b
Higham, Andrew
d88319ca-aab2-4b79-a3f5-d1330809cc79
Singh, Dave
5a8e5ba8-f961-4422-9a21-a6ef346041e5
Olsson, Henric
bdd651ee-bc1e-40ec-9d1e-17efe7419c7a
Owen, Caroline A.
e8d7464d-82d7-4457-b9d6-315f772c5ccc

Wang, Xiaoyun, Polverino, Francesca, Rojas-Quintero, Joselyn, Zhang, Duo, Sánchez, José, Yambayev, Ilyas, Lindqvist, Eva, Virtala, Robert, Djukanovic, Ratko, Davies, Donna E., Wilson, Susan, O'Donnell, Rory, Cunoosamy, Danen, Hazon, Petra, Higham, Andrew, Singh, Dave, Olsson, Henric and Owen, Caroline A. (2018) A Disintegrin and Metalloproteinase Domain-9: A novel proteinase culprit with multifarious contributions to COPD. American Journal of Respiratory and Critical Care Medicine, 198 (12), 1500-1518. (doi:10.1164/rccm.201711-2300OC).

Record type: Article

Abstract

INTRODUCTION: Proteinases with a disintegrin and a metalloproteinase domain (ADAMs) have not been well studied in COPD. We investigated whether ADAM9 is linked to COPD in humans and mice.

METHODS: ADAM9 blood and lung levels were measured in COPD patients versus controls, and air- versus cigarette smoke (CS)-exposed wild-type (WT) mice. WT and Adam9-/- mice were exposed to air or CS for 1-6 months, and COPD-like lung pathologies were measured.

RESULTS: ADAM9 staining was increased in lung epithelial cells and macrophages in smokers and even more so in COPD patients and correlated directly with pack-year smoking history and inversely with airflow obstruction and/or FEV1 % predicted. Bronchial epithelial cell ADAM9 mRNA levels were higher in COPD patients than controls and correlated directly with pack-year smoking history. Plasma, BALF and sputum ADAM9 levels were similar in COPD patients and controls. CS exposure increased Adam9 levels in WT murine lungs. Adam9-/- mice were protected from emphysema development, small airway fibrosis, and airway mucus metaplasia. CS-exposed Adam9-/- mice had reduced lung macrophage counts, alveolar septal cell apoptosis, lung elastin degradation, and shedding of VEGFR2 and EGFR in BALF samples. Recombinant ADAM9 sheds EGF and VEGF receptors from epithelial cells to reduce activation of the Akt pro-survival pathway and increase cellular apoptosis.

CONCLUSIONS: ADAM9 levels are increased in COPD lungs and linked to key clinical variables. Adam9 promotes emphysema development, and large and small airway disease in mice. Inhibition of ADAM9 could be a therapeutic approach for multiple COPD phenotypes.

Text
ADAM9 FINAL ONLINE - Accepted Manuscript
Download (3MB)

More information

Accepted/In Press date: 4 June 2018
e-pub ahead of print date: 4 June 2018
Published date: 15 December 2018
Keywords: Journal Article

Identifiers

Local EPrints ID: 424858
URI: http://eprints.soton.ac.uk/id/eprint/424858
ISSN: 1073-449X
PURE UUID: cea0d2fe-8977-417b-8848-8c5048997a30
ORCID for Ratko Djukanovic: ORCID iD orcid.org/0000-0001-6039-5612
ORCID for Donna E. Davies: ORCID iD orcid.org/0000-0002-5117-2991
ORCID for Susan Wilson: ORCID iD orcid.org/0000-0003-1305-8271

Catalogue record

Date deposited: 05 Oct 2018 11:50
Last modified: 16 Mar 2024 06:45

Export record

Altmetrics

Contributors

Author: Xiaoyun Wang
Author: Francesca Polverino
Author: Joselyn Rojas-Quintero
Author: Duo Zhang
Author: José Sánchez
Author: Ilyas Yambayev
Author: Eva Lindqvist
Author: Robert Virtala
Author: Donna E. Davies ORCID iD
Author: Susan Wilson ORCID iD
Author: Rory O'Donnell
Author: Danen Cunoosamy
Author: Petra Hazon
Author: Andrew Higham
Author: Dave Singh
Author: Henric Olsson
Author: Caroline A. Owen

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×